Abstract
A recent study reports a novel small molecule inhibitor of MCL-1 with efficacy in killing MCL-1-dependent cancer cells in vitro and in vivo. With the advent of S63845, the targeting of BCL-2, BCL-XL, and MCL-1 is now possible in vivo, but optimal clinical use is yet to be determined.
Copyright © 2016 Elsevier Inc. All rights reserved.
MeSH terms
-
Animals
-
Apoptosis
-
Cell Survival / drug effects
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Molecular Targeted Therapy
-
Myeloid Cell Leukemia Sequence 1 Protein / metabolism*
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Pyrimidines / pharmacology*
-
Pyrimidines / therapeutic use
-
Thiophenes / pharmacology*
-
Thiophenes / therapeutic use
Substances
-
MCL1 protein, human
-
Myeloid Cell Leukemia Sequence 1 Protein
-
Pyrimidines
-
S63845
-
Thiophenes